PER® Global to Present a Medical Crossfire®: Leveraging the Lung Cancer Team in Stage 3 NSCLC With Immuno-Oncology Strategies
PER® Global, a worldwide leading resource for continuing medical education (CME), will host the live CME-accredited Medical Crossfire®: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies, adjunct to the IASLC 2019 World Conference on Lung Cancer. The program will take place on Sunday, 08 Sept. 2019 from 11:30 a.m. to 13:30 p.m. in Hall 6 at Fira de Barcelona ? Gran Via venue in Spain.
The Medical Crossfire® will be chaired by Naiyer A. Rizvi, M.D., professor of medicine; director, thoracic oncology; co-director, cancer immunotherapy program; and the Price Family Professor of Medicine, Columbia University Irving Medical Center.
"The contemporary treatment of NSCLC requires the coordination and cooperation of the full treatment team," said Phil Talamo, president of PER® Global. "Through our Medical Crossfire® format, we will bring together pathology, medical oncology, and radiation oncology to foster a detailed discussion of the current and future of care for patients with non-small cell lung cancer (NSCLC)."
The variety of treatment options for patients with NSCLC continue to evolve, further complexifying the treatment landscape for this multifaceted illness. This program will feature a multidisciplinary faculty, world-renowned experts in medical oncology, radiation oncology and surgery. Current standards of care in patients with unresectable stage 3 NSCLC will be addressed, including the current and future roles of biomarkers and management of immune-related adverse events. Throughout the program, expert Medical Crossfire® discussion panels will illustrate how experts address challenges in the implementation of immunotherapy for patients with locally advanced NSCLC.
The faculty panel includes the following experts:
- Keith M. Kerr, FRCPath, consultant pathologist, department of pathology, Aberdeen Royal Infirmary, and professor of pulmonary pathology, Aberdeen University Medical School.
- Suresh Senanm, MRCP, FRCR, Ph.D., professor of clinical experimental radiotherapy, department of radiation oncology. Amsterdam University Medical Center.
- Rolf A. Stahel, M.D., professor in the oncology clinic, University Hospital Zurich.
This live activity is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 2 European CME credits for physicians. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Creditstm. For more information and to register, click here.
About Physicians' Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciencestm, the largest privately held, independent, full-service medical media company in the U.S. dedicated to delivering trusted health care news across multiple channels.
News published on and distributed by:
